Phaseline

Companies › Bio-Thera Solutions

Bio-Thera Solutions: clinical trials, targets and expected readouts

8 active drug programs in 11 registered trials: 7 Phase 1, 3 Phase 2, 1 Phase 3; Oncology, Ophthalmology, Neurology, Genitourinary; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BAT5906
Anti-VEGF monoclonal antibody
–Phase 3Diabetic Macular Edema (DME)Apr 2027
BAT1308
anti-PD-1 monoclonal antibody
PDCD1Phase 2Cervical Cancer; Advanced Solid TumorsNov 2026
BAT4406F
Anti-AQP4 monoclonal antibody
AQP4Phase 2Optic Neuromyelitis Spectrum Disease; Minimal Change Disease (MCD)Dec 2027
BAT8008 for Injection
Recombinant humanized anti-Trop2 monoclonal antibody conjugated to exatecan
TROP2Phase 1Advanced Solid TumorsNov 2026
BAT6026
Monoclonal antibody
–Phase 1Dermatitis, AtopicDec 2026
Pembrolizumab (BAT3306)
Programmed cell death protein 1 inhibitor
PDCD1Phase 1Carcinoma, Non-Small-Cell LungFeb 2027
BAT1006 for Injection–Phase 1Advanced Solid TumorsFeb 2028
BAT8010 for Injection
HER2-directed antibody or immunoconjugate
–Phase 1Advanced Solid TumorsFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06341114BAT1308Phase 1Advanced Solid TumorsOncologyNov 2026
NCT06341114BAT8008 for InjectionPhase 1Advanced Solid TumorsOncologyNov 2026
NCT06094179BAT6026Phase 1Dermatitis, AtopicImmunologyDec 2026
NCT06123884BAT1308Phase 2Cervical CancerOncologyJan 2027
NCT07180862Pembrolizumab (BAT3306)Phase 1Carcinoma, Non-Small-Cell LungOncologyFeb 2027
NCT07515079BAT5906Phase 3Diabetic Macular Edema (DME)OphthalmologyApr 2027
NCT05620017BAT8008 for InjectionPhase 1Advanced Solid TumorsOncologyMay 2027
NCT06044350BAT4406FPhase 2Optic Neuromyelitis Spectrum DiseaseNeurologyDec 2027
NCT06376136BAT8010 for InjectionPhase 1Advanced Solid TumorsOncologyFeb 2028
NCT06376136BAT1006 for InjectionPhase 1Advanced Solid TumorsOncologyFeb 2028
NCT07499700BAT4406FPhase 2Minimal Change Disease (MCD)GenitourinaryOct 2030

From the company's SEC filings

Complete response letters from FDA

Targets

PDCD1 (2) AQP4 (1) TROP2 (1)

Companies with the same targets

Akeso Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech Mabwell (Shanghai) Bioscience AstraZeneca GSK Shenyang Sunshine Pharmaceutical Regeneron Pharmaceuticals Ono Pharmaceutical

Companies built like this

Mabwell (Shanghai) Bioscience Sichuan Baili Pharmaceutical CSPC Megalith Biopharmaceutical CStone Pharmaceuticals TaiRx

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.